Innovative Cardiovascular Solutions said today it raised $5 million in an oversubscribed Series B round of financing to support its Emblok embolic protection system.
The Emblok system is an embolic protection device designed for full circumferential aortic collection while protecting the cerebral, abdominal and peripheral vasculature from embolic debris. The system is designed for use in transcatheter aortic valve replacement and structural heart procedures, theKalamazoo, Mich.-based company said.
The system includes an integrated 4 French radiopaque pigtail catheter to provide constant visualization and eliminate the need for dye injections to confirm positioning.
“The Emblok system is intuitive and easy to use. It is the only system to provide full capture and protection from embolic material released during TAVR and has become a necessary addition in my left heart interventions,” Dr. Azeem Latib of Milan, Italy’s San Raffaele Hospital said in a prepared statement.
Proceeds from the funding round will support further device development and the initiation of a 510(k) study of the device in the US.
“ICS has made tremendous progress in the past 12 months with the initiation of human clinical cases in Milan, Italy. At the halfway mark of study enrollment, initial results look promising. We are pleased by the strong vote of confidence from our investors supporting the pursuit of this innovative and comprehensive approach to embolic protection,” co-founder & CEO R. Plemmons said in a press release.
In April, ICS reported raising $3.1 million in a round of equity financing, according to an SEC filing. Money in the round came from 97 unnamed sources, with the 1st sale recorded on July 14, 2015.